GLP-1 Patients Quit Then Return, New Study Reveals
What happens when patients stop taking a GLP-1? New real-world data reveals that more than half eventually come back, and it may completely change the way we think about obesity treatment. In this week's On The Pen Podcast, we're breaking down one of the biggest shifts happening in obesity medicine. We dive into new research on GLP-1 persistence, the early challenges facing Medicare's obesity drug rollout, and why pharmaceutical companies are racing to solve the problems patients have been talking about for years. We also discuss the next generation of obesity therapies, including oral GLP-1s, implantable medications, muscle-preserving treatments, and why the future of obesity medicine may be less about losing more weight and more about helping patients stay healthy for the long term. In this episode: • Why patients who stop GLP-1 therapy often return • The first weeks of Medicare's obesity medication coverage • The future of oral GLP-1 medications • New implant technology from Novo Nordisk • Muscle-preserving obesity treatments • Why patient experience is becoming the next frontier in obesity medicine The goal of On The Pen has always been simple: translate complex obesity and diabetes news into information that helps you have better conversations with your doctor. 👇 What has been your biggest obstacle to staying on treatment? Insurance? Cost? Side effects? Tell us in the comments. 📰 Read more obesity medicine news: https://OnThePen.com 📩 Subscribe to my free newsletter: https://obesity.news 🔗 All my links: https://OTPLINKS.com 👍 If you found this helpful, please Like, Subscribe, and Share this episode with someone navigating obesity, diabetes, or GLP-1 treatment. #GLP1 #Obesity #WeightLoss #Zepbound #Mounjaro #Ozempic #Wegovy #ObesityMedicine #Type2Diabetes #OnThePen #Healthcare #Medicare #Podcast WAYS TO SUPPORT MY WORK ⬇️ 💊 OVER THE COUNTER ORAL PEPTIDE SUPPLIMENTS: BPC-157 // Can’t Weight // TB4-FRAG // KPV Sign up here and use code “OTP10” to save 10% https://integrativepeptides.com/OTP
Foundayo’s ADA Data Looks Strong, but There Is a Catch
150: Why Tirzepatide Works Better Than GLP-1 Alone
Anytime Fitness · She Stopped Running Her Gym. Now She Runs 15. Amanda Reinsburger
BREAKING: China’s ENTIRE Housing Market Just Collapsed
Hypermobility Syndromes: The Hidden Pattern Behind 4 Separate Diagnoses.A chat with Dr John Campbell
Eli Lilly CEO: How GLP-1s Will Reshape America
The **NEW** Korean Treatment Replacing FaceLifts !!
GLP-1 Not Working Like Before? Weight Loss Plateaus, Fatigue, and the Middle
Never Set a Goal Weight on a GLP-1 (Do This Instead)
GLP-1s 7X More Likely to Keep the Weight Off? The New Data Is Stunning
DO THIS To DOUBLE Your GLP-1 Results to MAXIMIZE Weight Loss
Why I Take Low-Dose Tirzepatide (& Not Retatrutide)
Forget Zepbound: 15 New Obesity Drugs Are Coming
EP. 212 | Obesity Isn’t A Willpower Problem: The Role Of GLP-1s | Dr. Spencer Nadolsky
12 GLP-1 Tips That Helped Me Drop 100 lbs
New Study Shows How To Keep Weight Off When No Longer Using GLP1's (Doctor Reation) | Solo Ep 247
What Really Works for Weight Loss: GLP-1 Power Tools for Men!
The Truth About GLP-1 Maintenance No One is Talking About | Docs Who Lifts
I'm a Pathologist. Ozempic & Mounjaro Aren't Actually Weight Loss Drugs.
